Bristol Myers Squibb (BMY) Stock Moves -0.4%: What You Should Know
Bristol Myers Squibb (BMY) closed at $67.24 in the latest trading session, marking a -0.4% move from the prior day....…
55,740€
1,42%
Echtzeit-Aktienkurs Bristol-Myers Squibb Co.
Bid:
Ask:
Nachrichten zur Bristol-Myers Squibb Co. Aktie
Is Bristol Myers Squibb Stock A Better Pick Over Its Industry Peer?
Investors have assigned a higher multiple to LLY stock due to its robust pipeline and better profitability, as discussed below…
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Bristol Myers Squibb (BMY) closed at $67.10, marking a -0.56% move from the previous day....…
Evotec Shares Rise After Drug Progress Earns Payment From Bristol Myers Squibb
Evotec Shares Rise After Drug Progress Earns Payment From Bristol Myers Squibb...…
Evotec Announces Progress In Protein Degradation Partnership With Bristol Myers
NEW YORK CITY (dpa-AFX) - Evotec SE (EVO) announced progress in strategic protein degradation partnership with Bristol Myers Squibb. Performance-based…
Evotec SE: Evotec Announces Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
KEY SCIENTIFIC ACHIEVEMENTS DRIVE THE EXPANSION OF THE PIPELINE OF MOLECULAR GLUE DEGRADERSPERFORMANCE-BASED AND PROGRAMME-BASED PAYMENTS OF IN TOTAL US$…
Evotec erhält 75 Mio Dollar aus Bristol-Myers-Partnerschaft
FRANKFURT (Dow Jones)--Evotec macht im Rahmen der Partnerschaft mit Bristol Myers Squibb bei der Pipelineentwicklung von Molecular Glues Fortschritte und…
Fortschritte in Forschungskooperation mit BMS: Evotec erhält Millionenzahlung
HAMBURG (dpa-AFX) - Der Wirkstoffforscher Evotec (EVOTEC SE) erhält nach Fortschritten in der Kooperation mit dem Pharmakonzern Bristol Myers Squibb…
Mediar Therapeutics announces $105m financing to advance fibrosis therapies
The Series A round was co-led by Novartis Venture Fund and Sofinnova Partners and has seen participation from Pfizer Ventures,…
Corporate News: Evotec SE
Evotec verkündet Fortschritte in strategischer Partnerschaft mit Bristol Myers Squibb im Bereich Protein Degradation...…
Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation
.../WASHINGTON (Reuters) - The blood thinner Eliquis from Bristol Myers... and academic analyses shared with Reuters.
…
Should Investors Buy Bristol Myers or CVS Stock Near 52-week Lows?
Investors are often on the lookout for strong companies that may be undervalued and present lucrative long-term opportunities....…
Bristol Myers Squibb (BMY) Stock Moves -1.19%: What You Should Know
In the latest trading session, Bristol Myers Squibb (BMY) closed at $65.72, marking a -1.19% move from the previous day....…
Bristol Myers (BMY) Gets EU Nod for Anemia Drug Reblozyl
Bristol Myers Squibb (BMY) gets full marketing authorization from the European Commission, for Reblozyl for anemia associated with non-transfusion-dependent beta…
Bristol-Myers Squibb Company declares $0.57 dividend
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Viz.ai schließt Vereinbarung mit Bristol Myers Squibb, um frühere Erkennung und Behandlung von vermuteter hypertropher Kardiomyopathie (HCM) zu ermöglichen
SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, ein führendes Unternehmen im Bereich der KI-gestützten Krankheitserkennung und Pflegekoordination, gab heute eine mehrjährige Vereinbarung mit Bristol…
Bristol Myers, Janssen launch late-stage Librexia program evaluating milvexian
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Bristol Myers wins $6.4B lawsuit over cancer drug delay
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Bristol Myers wins dismissal of lawsuit over Celgene drugs
...NEW YORK (Reuters) - A U.S. judge on Wednesday dismissed......…
Bristol Myers Opdivo for skin cancer gets review in US, EU
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K BRISTOL MYERS SQUIBB CO For: Feb 23
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Friendly Forces Partners with Bristol Myers Squibb to Promote Pro-Reservist Policies and Hiring
WASHINGTON, Feb. 23, 2023 /PRNewswire/ -- Friendly Forces, a new company that identifies employers of choice for military reservists, makes…
Bristol Myers Squibb Company: Basketball Legend Kareem Abdul-Jabbar Joins No Time to Wait Campaign to Raise Awareness of Atrial Fibrillation and its Symptoms
PRINCETON, NJ and NEW YORK, NY / ACCESSWIRE / February 21, 2023 / Bristol Myers Squibb CompanyOriginally published on Bristol…
Lung Cancer Drugs Global Market Report 2023
NEW YORK, Feb. 21, 2023 /PRNewswire/ -- Major players in the lung cancer market are Bristol-Myers Squibb Company, Merck &…
Bladder Cancer Drugs Global Market Report 2023
NEW YORK, Feb. 17, 2023 /PRNewswire/ --Major players in the bladder cancer drugs market are Pfizer, Celgene Corporation, Eli Lilly,…
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....…
Cervical Cancer Drugs Global Market Report 2023
NEW YORK, Feb. 16, 2023 /PRNewswire/ -- Major players in the cervical cancer drugs market are F. Hoffmann-La Roche Ltd,…
Skye Bioscience Appoints Deborah Charych, PhD to Board of Directors
San Diego, California--(Newsfile Corp. - February 16, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical…
HDAC (Histone Deacetylase) Inhibitors Market to Grow by USD 172.61 Mn, Curis Inc. and Bristol Myers Squibb Co. Among Key Vendors - Technavio
NEW YORK, Feb. 13, 2023 /PRNewswire/ -- The HDAC (histone deacetylase) Inhibitors Market by Route of Administration, Distribution Channel, and…
Monoclonal Antibodies (MAbS) Global Market Report 2023
NEW YORK, Feb. 13, 2023 /PRNewswire/ -- Major players in the monoclonal antibodies (MABS) market are Johnson & Johnson, Merck,…
Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients
read more...…
Bristol-Myers, 2seventy post late-stage data for CAR-T therapy in multiple myeloma
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: EVP, Chief Human Resources verkauft Aktien von Bristol-Myers Squibb Company im Wert von 835.258$
Powell, Ann - Vorstand - Tag der Transaktion: 2023-02-06...…
Insiderhandel: Board Chair and CEO verkauft Aktien von Bristol-Myers Squibb Company im Wert von 17.916.000$
Caforio, Giovanni - Vorstand - Tag der Transaktion: 2023-02-06...…
Bristol Myers Squibb Company: Reflecting on Research in Genitourinary Cancers
NORTHAMPTON, MA / ACCESSWIRE / February 6, 2023 / Originally published on Bristol Myers Squibb News & PerspectivesDana Walker, MD,…
Will These 3 Potential Blockbuster Drugs Lift Bristol Myers Squibb?
Bristol Myers Squibb has solid replacements for its blockbusters that are facing a patent cliff....…
What 5 Analyst Ratings Have To Say About Bristol-Myers Squibb
Latest Ratings for BMY
DateFirmActionFromTo Mar 2022Wells FargoMaintainsEqual-Weight Dec 2021Goldman SachsInitiates Coverage OnBuy Dec 2021Wells FargoInitiates Coverage OnEqual-Weight
…
Bristol-Myers (BMY) Q4 Earnings Top, Revlimid Generic Impact Sales
Bristol-Myers (BMY) fourth-quarter 2022 earnings beat estimates, while sales declined year over year due to generic erosion for oncology drug…
Compared to Estimates, Bristol Myers (BMY) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the…
Bristol-Myers Squibb (BMY) Q4 2022 Earnings Call Transcript
BMY earnings call for the period ending December 31, 2022....…
Exscientia kündigt erste Studie am Menschen für den von Bristol Myers Squibb lizenzierten PKC-Theta-Inhibitor EXS4318 an
OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) gab heute bekannt, dass EXS4318 (4318), ein Wirkstoff, der von Exscientia entwickelt und von…
Bristol Myers Profit Tops Estimates but Revenue Falls on Lower Revlimid Sales
Bristol Myers posts fourth-quarter earnings of $1.82 a share on revenue of $11.4 billion....…
Bristol-Myers Squibb Guides FY23 Adj. EPS In Line; Q4 Results Top Estimates
NEW YORK CITY (dpa-AFX) - While reporting financial results for the fourth quarter on Thursday, biopharmaceutical company Bristol-Myers Squibb Co.…
Bristol Myers Squibb sees revenue fall in Q4
Shares of Bristol Myers Squibb Co. BMY gained 0.9% in premarket trading on Thursday after the company announced better-than-expected earnings…
Bristol Myers Q4 earnings sag on lower Revlimid sales
...By Michael Erman
(Reuters) - Drugmaker Bristol Myers Squibb said......…
Bristol-Myers Squibb Company Non-GAAP EPS of $1.82 beats by $0.09, revenue of $11.4B beats by $200M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Will Bristol Myers Q4 revenues see boost from potential blockbuster Sotyktu?
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K BRISTOL MYERS SQUIBB CO For: Jan 29
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Earnings Previews: Bristol-Myers Squibb, ConocoPhillips, Merck, Sirius XM
These four companies, including one Dow Jones industrial, are set to report quarterly earnings early Thursday....…
How Will Bristol Myers Squibb Stock Trend Post Q4 Results?
A decline in Revlimid sales will likely more than offset sales growth for Eliquis, Opdivo, and Reblozyl....…